MGH Institute of Health Professions, Boston, MA.
Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA.
Genet Med. 2024 Jun;26(6):101115. doi: 10.1016/j.gim.2024.101115. Epub 2024 Mar 1.
Exome (ES) and genome sequencing (GS) are increasingly being utilized for individuals with rare and undiagnosed diseases; however, guidelines on their use remain limited. This study aimed to identify factors associated with diagnosis by ES and/or GS in a heterogeneous population of patients with rare and undiagnosed diseases.
In this case control study, we reviewed data from 400 diagnosed and 400 undiagnosed randomly selected participants in the Undiagnosed Diseases Network, all of whom had undergone ES and/or GS. We analyzed factors associated with receiving a diagnosis by ES and/or GS.
Factors associated with a decreased odds of being diagnosed included adult symptom onset, singleton sequencing, and having undergone ES and/or GS before acceptance to the Undiagnosed Diseases Network (48%, 51%, and 32% lower odds, respectively). Factors that increased the odds of being diagnosed by ES and/or GS included having primarily neurological symptoms and having undergone prior chromosomal microarray testing (44% and 59% higher odds, respectively).
We identified several factors that were associated with receiving a diagnosis by ES and/or GS. This will ideally inform the utilization of ES and/or GS and help manage expectations of individuals and families undergoing these tests.
外显子组(ES)和基因组测序(GS)越来越多地用于患有罕见和未确诊疾病的个体;然而,其使用指南仍然有限。本研究旨在确定在罕见和未确诊疾病的患者的异质人群中,与 ES 和/或 GS 诊断相关的因素。
在这项病例对照研究中,我们回顾了未确诊疾病网络中 400 名确诊和 400 名随机选择的未确诊参与者的数据,所有参与者均接受了 ES 和/或 GS 检测。我们分析了与通过 ES 和/或 GS 获得诊断相关的因素。
与诊断可能性降低相关的因素包括成人发病、单样本测序以及在被纳入未确诊疾病网络之前接受 ES 和/或 GS 检测(分别降低 48%、51%和 32%的可能性)。增加通过 ES 和/或 GS 获得诊断可能性的因素包括主要表现为神经系统症状和先前进行过染色体微阵列检测(分别增加 44%和 59%的可能性)。
我们确定了与通过 ES 和/或 GS 获得诊断相关的几个因素。这将有助于指导 ES 和/或 GS 的使用,并有助于管理接受这些检测的个体和家庭的期望。